Latest Updates



Investor Event

Geron to participate at investor conferences in April

John Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, to present at the 23rd Annual Needham Virtual Healthcare Conference on April 10 and Stifel’s 2024 Virtual Targeted Oncology Days on April 17.

Medical Congress

Geron data presentations at NCCN and HOPA 2024 Annual Conferences

Geron presented data at the National Comprehensive Cancer Network (NCCN) Annual Conference and the Hematology/Oncology Pharmacy Association Annual Conference (HOPA).

What if you could kill cancer cells by targeting the enzyme that drives their uncontrolled growth?

Geron is tirelessly pursuing blood cancer treatments with the potential to extend and enhance lives through the unique mechanism of action of telomerase inhibition. Our first-in-class investigational telomerase inhibitor, imetelstat, harnesses Nobel Prize-winning science in a treatment that may alter the underlying drivers of disease.